Article metrics

other Versions

Download PDFPDF

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2022

AbstractFullPdf
Nov 2021455430230
Dec 2021842820318
Jan 202213651386450
Feb 2022882881249
Mar 2022800801225
Apr 2022479493132
May 2022570576161
Jun 2022386388118
Jul 2022346341122
Aug 202215313850
Total627862542055